DeepMB: A Deep Learning Framework For High-Quality Optoacoustic Imaging in Real-Time
mehr
Storys zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Takeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
mehrPress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
mehrTake a Deep Breath: Early Detection of Vascular Disease in Chronic Lung Disease of Premature Infants
Premature infants often struggle with breathing and require ventilatory support and oxygen therapy. Unfortunately, this might lead to lung damage resulting in lifelong consequences and chronic disease. Dr. Anne Hilgendorff’s team from Helmholtz Munich and the LMU University Hospital developed a non-invasive ...
mehr- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehr
- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
Ein Dokumentmehr A New Ally in Fighting Brain Diseases: Our Very Own Skull
mehr- 4
PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data Sets
mehr Life Science Factory to Open a New Location in Munich in 2024
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehrTechnische Universität München
4D printing for nerve stimulation: Self-folding electrodes stimulate fine nerves
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Self-folding electrodes stimulate fine nerves 4D printing for nerve stimulation - Researchers have produced very fine, flexible electrodes - Upon contact with tissue moisture, the electrodes wrap themselves around thin nerves - Nerve stimulation and recording with the foldable electrodes has already been demonstrated in ...
mehr
WildDISCO: Visualizing Whole Bodies in Unprecedented Detail
mehrPotentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
mehr- 2
CARAMBA: New Hope for Multiple Myeloma Patients
mehr New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrEmpowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
mehr
Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth / Phase II study for BC 007 in the indication Long COVID to start in June
mehrFirst Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
mehrUnraveling the Mode of Action of Tirzepatide
Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the contribution of activating the GIP receptor in the overall efficacy of ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrDiagnosis of Type 1 Diabetes After SARS-CoV-2 Infection: Researchers Find Possible Correlation
During the COVID-19 pandemic, an increase in the chronic autoimmune disease type 1 diabetes was observed in children, also in Germany. Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern (KVB), have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the ...
mehrGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
mehr
DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrNeuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Barcelona, Spain, Düsseldorf, Germany and Paris (ots/PRNewswire) - Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group ("Neuraxpharm"), the leading European specialty pharmaceutical company focused on ...
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehr- 5
Press Release - hubergroup India expands its support for rural healthcare
Ein Dokumentmehr The world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
mehrInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
Ein Dokumentmehr
Vorherige12345678910Nächste